Nyxoah (NYXH) has released an update.
Nyxoah, a medical tech firm specializing in Obstructive Sleep Apnea solutions, has secured a €37.5 million loan from the European Investment Bank, supported by the European Commission’s InvestEU program, to boost R&D and manufacturing. The loan is structured in three tranches with conditional disbursements and includes a synthetic warrant agreement with EIB. CEO Olivier Taelman expresses gratitude for the support which complements a recent equity offering, bringing their growth capital to over €80 million.
For further insights into NYXH stock, check out TipRanks’ Stock Analysis page.
